Deep vein thrombosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
| Line 3: | Line 3: | ||
'''Phase 3 Trials''' | '''Phase 3 Trials''' | ||
Acute Medically Ill [[venous thromboembolism]] (VTE) Prevention With Extended Duration Betrixaban Study (The APEX Study): Sponsored by Portola Pharmaceuticals | |||
* Primary Outcome Measures: Composite of VTE (DVT and/or PE) and VTE death | |||
* Secondary Outcome Measures: Number of patients with symptomatic VTE | |||
* Estimated Enrollment: 6850 | |||
* Study Start Date: March 2012 | |||
* Estimated Study Completion Date: December 2014 | |||
* | |||
Efficacy and Safety Study of Apixaban for Extended Treatment of [[Deep Vein Thrombosis]] or [[Pulmonary Embolism]]: Sponsored by Bristol-Myers Squibb and Pfizer <ref>http://clinicaltrials.gov/ct2/show/NCT00633893</ref> | |||
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism: Sponsored by Bristol-Myers Squibb and Pfizer <ref>http://clinicaltrials.gov/ct2/show/NCT00633893</ref> | |||
* Primary Outcome Measures: Venous Thromboembolic Recurrence or Death | * Primary Outcome Measures: Venous Thromboembolic Recurrence or Death | ||
* Secondary Outcome Measures: Bleeding | * Secondary Outcome Measures: Bleeding | ||
Revision as of 01:38, 20 June 2012
Ongoing Research
Phase 3 Trials
Acute Medically Ill venous thromboembolism (VTE) Prevention With Extended Duration Betrixaban Study (The APEX Study): Sponsored by Portola Pharmaceuticals
- Primary Outcome Measures: Composite of VTE (DVT and/or PE) and VTE death
- Secondary Outcome Measures: Number of patients with symptomatic VTE
- Estimated Enrollment: 6850
- Study Start Date: March 2012
- Estimated Study Completion Date: December 2014
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism: Sponsored by Bristol-Myers Squibb and Pfizer [1]
- Primary Outcome Measures: Venous Thromboembolic Recurrence or Death
- Secondary Outcome Measures: Bleeding
- Estimated Enrollment: 2,430 patients
- Study Start Date: May 2008
- Estimated Study Completion Date: August 2012